Skip to content
Open access · OA via Europe PMC

Therapeutic Immune Reprogramming by Rapamycin Attenuates Plaque Inflammation and Lymphoid Immune Responses in Aged Atherosclerotic Mice.

de Mol J, de Korte DH, Depuydt MAC, Smit V, Kleijn MNAB, van Santbrink PJ, Binder CJ, Porsch F, Schaftenaar FH, Foks AC.

Aging cell · 2026

Abstract

Aging is a major risk factor for atherosclerosis and is accompanied by profound changes in the immune system, including effector T cell expansion, senescent cell accumulation, and increased pro-inflammatory signaling. mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">Rapamycin(definition), a promising rejuvenation therapeutic that inhibits mTORC1 and modulates immune aging, was investigated for its potential to attenuate pro-atherogenic immune responses in aged atherosclerotic mice. 80- to 90-week-old male Ldlr<sup>-/-</sup> mice with established atherosclerotic lesions were treated intraperitoneally with rapamycin or control triweekly for 8 weeks. Systemic and plaque immunity was assessed by flow cytometry or single-cell RNA-sequencing. Plaque morphology was evaluated by histology. Rapamycin treatment reduced plaque macrophage content (0.73 ± 0.07 × 10<sup>5</sup> μm<sup>2</sup>) compared to control (ctrl: 0.95 ± 0.09 × 10<sup>5</sup> μm<sup>2</sup>, p < 0.05) and decreased total T cell numbers in vascular and lymphoid tissues. This was accompanied by a shift from effector to central memory phenotypes, particularly within the CD8<sup>+</sup> compartment, and a relative enrichment of regulatory CD4<sup>+</sup> T cells (Tregs). Single-cell transcriptomics of aortic Tregs revealed increased expression of suppressive genes (Foxp3, Tgfb1) upon rapamycin. Rapamycin also reduced T follicular helper cells, IL-21 expression, germinal center B cells, plasma cells, and total and oxidation-specific epitope-specific immunoglobulin levels. Additionally, age-associated B cells were diminished in spleen and lymph nodes, reflecting a broader anti-inflammatory effect on B cell immunity. Finally, aortic leukocytes displayed profoundly reduced senescent enrichment scores. Rapamycin remodels the immune landscape in aged atherosclerotic mice, promoting regulatory lymphocyte subsets and suppressing antigen-driven and inflammatory immune responses. These findings highlight the potential of immune-targeted rejuvenation to mitigate age-related atherogenic inflammation.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
Europe PMC
DOI
10.1111/acel.70730
Canonical
link ↗
Fetched
2026-10-07 MST

Cite this

APA
J, D.M., DH, D.K., MAC, D., V, S., MNAB, K., PJ, V.S., CJ, B., F, P., FH, S., &amp; AC., F. (2026). Therapeutic Immune Reprogramming by Rapamycin Attenuates Plaque Inflammation and Lymphoid Immune Responses in Aged Atherosclerotic Mice. <em>Aging cell</em>. https://doi.org/10.1111/acel.70730
Vancouver
J DM, DH DK, MAC D, V S, MNAB K, PJ VS, et al. Therapeutic Immune Reprogramming by Rapamycin Attenuates Plaque Inflammation and Lymphoid Immune Responses in Aged Atherosclerotic Mice. Aging cell. 2026. doi:10.1111/acel.70730.
BibTeX
@article{de2026Therap, title = {Therapeutic Immune Reprogramming by Rapamycin Attenuates Plaque Inflammation and Lymphoid Immune Responses in Aged Atherosclerotic Mice.}, author = {de Mol J and de Korte DH and Depuydt MAC and Smit V and Kleijn MNAB and van Santbrink PJ and Binder CJ and Porsch F and Schaftenaar FH and Foks AC.}, journal = {Aging cell}, year = {2026}, doi = {10.1111/acel.70730}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings